{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:08:58Z","timestamp":1790726938923,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that primarily affects the intertriginous regions, causing manifestations such as inflammatory nodules, abscesses and scarring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically evaluate the efficacy and safety of interleukin (IL)-17 inhibitors, including bimekizumab and secukinumab, for the treatment of moderate-to-severe HS based on evidence from randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched various electronic databases, including MEDLINE (via PubMed), Embase and CENTRAL to retrieve RCTs on the use of two IL-17 inhibitors (bimekizumab and secukinumab) for the management of HS. Dichotomous outcomes were reported as relative risk (RR) with 95% confidence intervals (CIs), and continuous outcomes were reported as mean difference (MD) with 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our meta-analysis included 5 RCTs with a total of 2188 patients. According to our analysis, IL-17 inhibitors significantly increased the proportion of patients with HiSCR50 (Hidradenitis Suppurativa Clinical Response) (RR 1.45, 95% CI 1.26\u20131.66) and HiSCR75 (RR 2.03, 95% CI 1.42\u20132.90). IL-17 inhibitors significantly increased the proportion of patients with Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) worst skin pain response (RR 2.46, 95% CI 1.41\u20134.30). The IL-17 inhibitor group was associated with a statistically significant decrease in HSSDD worst skin pain score from baseline compared with the placebo group (MD \u22121.02, 95% CI \u22121.44 to \u22120.60). The intervention group was also associated with a statistically significant decrease in Dermatology Life Quality Index score from baseline compared with the placebo group (MD \u22121.77, 95%\u00a0CI\u00a0\u22122.54 to \u22120.99). The treatment-emergent adverse events were similar in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IL-17 inhibitors are associated with an improvement in clinical response and pain outcomes in patients with moderate-to-severe HS, with an acceptable safety profile in the available studies. Given the limited number of trials with no head-to-head comparisons, further large-scale and independent studies are required to clarify their long-term role, particularly in patients whose HS is refractory to conventional and biologic therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag102","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:23:52Z","timestamp":1783700632000},"page":"712-721","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of two interleukin-17 inhibitors (bimekizumab and secukinumab) in the management of\u00a0hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"6","author":[{"given":"Hana","family":"Ishkirat","sequence":"first","affiliation":[{"name":"Department of Medicine, Arab American University , Ramallah ,","place":["Palestine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yozahandy Angeles","family":"Abarca-Pineda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medica Sur , Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Sharjah , Sharjah ,","place":["UAE"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Shamim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tbilisi State Medical University , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Elremmash","sequence":"additional","affiliation":[{"name":"Department of Medicine, Istinye University , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-3085","authenticated-orcid":false,"given":"Bilal\u00a0Haider","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Betsi Cadwaladr University Health Board , Bodelwyddan ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaz","family":"Mohsin","sequence":"additional","affiliation":[{"name":"Department of Acute Medicine, Royal Stroke University Hospital , Stoke-on-Trent ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F N U","family":"Deeksha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Government Medical College , Patiala ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teenu Maria","family":"Jeswin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Doncaster Royal Infirmary , Doncaster ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Government Medical College , Patiala ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma\u2019a\u00a0Munasar\u00a0Ali","family":"Alsubari","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Sana\u2019a University , Sana\u2019a ,","place":["Yemen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-7956","authenticated-orcid":false,"given":"Muhammad","family":"Ayyan","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Edward Medical University , Lahore ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026092919520299800_vzag102-B1","volume-title":"Stat\u00adPearls","author":"Ballard","year":"2025"},{"key":"2026092919520299800_vzag102-B2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0007-1226(03)00177-2","article-title":"Hidradenitis suppurativa: pathogenesis and management","volume":"56","author":"Slade","year":"2003","journal-title":"Br J Plast Surg"},{"key":"2026092919520299800_vzag102-B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-4632.2004.02536.x","article-title":"Hidradenitis suppurativa\u201d is acne inversa! An appeal to (finally) abandon a misnomer","volume":"44","author":"Sellheyer","year":"2005","journal-title":"Int J Dermatol"},{"key":"2026092919520299800_vzag102-B4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026092919520299800_vzag102-B5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjd.20954","article-title":"New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities","volume":"186","author":"Prens","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026092919520299800_vzag102-B6"},{"key":"2026092919520299800_vzag102-B7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026092919520299800_vzag102-B8","first-page":"868","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa \u2013 short version","volume":"22","author":"Zouboulis","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026092919520299800_vzag102-B9","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1111\/bjd.16768","article-title":"Current and future treatment of hidradenitis suppurativa","volume":"183","author":"van Straalen","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026092919520299800_vzag102-B10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026092919520299800_vzag102-B11","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026092919520299800_vzag102-B12","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2026092919520299800_vzag102-B13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2026092919520299800_vzag102-B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"2026092919520299800_vzag102-B15","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"2026092919520299800_vzag102-B16","author":"NICE"},{"key":"2026092919520299800_vzag102-B17","author":"Higgins"},{"key":"2026092919520299800_vzag102-B18"},{"key":"2026092919520299800_vzag102-B19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026092919520299800_vzag102-B20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence \u2013 imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026092919520299800_vzag102-B21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026092919520299800_vzag102-B22","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety\u00a0of\u00a0secukinumab over five years in patients with moderate-to-\u00adsevere plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2026092919520299800_vzag102-B23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092919520299800_vzag102-B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/12034754211035667","article-title":"Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review","volume":"26","author":"Kashetsky","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2026092919520299800_vzag102-B25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2026092919520299800_vzag102-B26","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3390\/pharmaceutics15102450","article-title":"IL-17 inhibition: a valid therapeutic strategy in the management of hidradenitis suppurativa","volume":"15","author":"Malvaso","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026092919520299800_vzag102-B27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/pharmaceutics15051351","article-title":"Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic review and network meta-analysis","volume":"15","author":"Tsai","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026092919520299800_vzag102-B28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026092919520299800_vzag102-B29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026092919520299800_vzag102-B30","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2270091","article-title":"Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review","volume":"34","author":"Vagnozzi","year":"2023","journal-title":"J Dermatolog Treat"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/712\/68755794\/vzag102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/5\/712\/68755794\/vzag102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:52:13Z","timestamp":1790725933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/5\/712\/8732062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,10]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag102","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,10]]}}}